Related Experiment Video
Updated: Jun 5, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Stroke prevention in atrial fibrillation: atrial appendage closure
1Cardiovascular Scientific Development, Swedish Medical Center, Seattle, WA 98122, USA. Cindy.fuller@swedish.org
Insights
Left atrial appendage occlusion offers a stroke prevention alternative for atrial fibrillation patients, potentially reducing reliance on anticoagulation and its associated risks.
Area of Science:
- Cardiology
- Neurology
- Medical Devices
Background:
- The left atrial appendage (LAA) is a major source of cardioembolic stroke in atrial fibrillation (AF) patients.
- Current anticoagulants (e.g., warfarin, dabigatran) have contraindications and drug interactions, limiting their use.
- Left atrial appendage occlusion (LAAO) is an emerging strategy for stroke prevention in AF.
Purpose of the Study:
- To review LAA anatomy and its role in ischemic stroke.
- To discuss outcomes of surgical and endovascular LAA occlusion trials in AF patients.
- To present data on novel LAA occlusion devices.
Main Methods:
- Literature review of LAA structure and stroke mechanisms.
- Analysis of clinical trial data for LAA occlusion efficacy and safety.
- Review of early-stage device development for LAA occlusion.
Main Results:
- LAA structure predisposes it to thrombus formation, a key cause of stroke in AF.
- LAA occlusion trials show promise in reducing stroke risk and adverse events.
- Various epicardial and endovascular devices are under investigation for LAA occlusion.
Conclusions:
- LAA occlusion presents a viable alternative to anticoagulation for stroke prevention in AF.
- Further research and device development are crucial for optimizing LAA occlusion therapies.
- LAAO may mitigate bleeding risks associated with long-term anticoagulation.
Abstract:
The left atrial appendage (LAA) is the primary nonvalvular cause of cardioembolic stroke in patients with atrial fibrillation (AF). Warfarin and direct thrombin inhibitors such as dabigatran are presumed to prevent formation of LAA thrombus, and are first-line treatments to prevent ischemic stroke in AF. However, these medications carry many contraindications such as hemorrhage, and can interact with many drugs and supplements. Epicardial and endovascular techniques for occlusion of LAA are being explored, whether to mitigate the need for anticoagulation in patients at risk of bleeding or as a first-line therapy to reduce the risk of thromboembolic stroke. The purposes of this article are to 1) review the LAA structure and its potential contribution to ischemic stroke; 2) discuss the results of surgical and endovascular trials of LAA occlusion on risk of stroke and adverse events in AF patients; and 3) present early data on devices in development.
